Lantheus Doubled In A Year Amid Wide Use Of Its Medical Devices

Artificial intelligence is the watchword for investors, but some analysts also see strength this year in the medical sector. Lantheus Holdings (LNTH) is a standout among medical device makers, and its devices use artificial intelligence.
Based on its strong fundamentals, Lantheus stock’s Relative Strength (RS) Rating crossed above a milestone as it got upgraded from 80 to 83 Tuesday.
↑
X
Stock Market Exposure: How To Make Incremental Portfolio Management Decisions
The upgraded 83 RS Rating shows that Bedford, Mass.-based Lantheus Holdings is in the top 17% of all stocks for price performance this past year. However, although strong, that rating is just catching up to its other outstanding ratings. Lantheus boasts an 89 Composite Rating out of 99 and a terrific 94 EPS Rating.
Lantheus AI-Enabled Medical Gear Is Widely Used
Lantheus makes radiopharmaceutical diagnostic devices used by a variety of health care professionals including nuclear medicine physicians, cardiologists, urologists, internal medicine physicians and others. It has also begun using artificial intelligence in its software.
Risk Management In The Stock Market: How Much Money To Invest Now
Notably, Lantheus stock nearly doubled in less than a year, rising from a 50.20 intraday low on Jan. 26 to a 96.92 close Tuesday, up 6.3% for the day.
Additionally, Lantheus holds the No. 8 rank among its peers in the 128-stock Medical-Products industry group. Globus Medical (GMED), Pro-Dex (PDEX) and Insulet (PODD) are among the top 5 highly rated stocks in the group.
Fundamentals Strong For ‘Steady Eddie’ Device Maker
In terms of fundamentals, Lantheus Holdings is a steady Eddie showing continuing growth. It reported 16% earnings growth in the latest quarterly report, to $1.70 per share. Sales grew 18% to $378.7 million. The prior three periods it recorded EPS gains of 28%, 15% and 17% as revenue rose 35%, 23% and 23%.
The exclusive Relative Strength Rating from Investor’s Business Daily tracks share price movement with a 1 (worst) to 99 (best) score. The score shows how a stock’s price movement over the last 52 weeks compares to all the other stocks in our database. Market research shows that the best-performing stocks tend to have an 80 or higher RS Rating in the early stages of their moves.
Please follow James DeTar on Twitter @JimDeTar
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
MarketSurge’s Tools Can Help The Individual Investor
How Relative Strength Line Can Help You Judge A Stock
Watch Our Market Experts Spot Top Stocks Each Morning On IBD Live
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
link